Gilenya loss of exclusivity uk?

When does Gilenya (fingolimod) lose exclusivity in the UK?

Gilenya’s “loss of exclusivity” in the UK can refer to different legal events, most commonly patent expiry and/or the end of other exclusivity protections that delay generic or biosimilar entry. The exact date depends on which specific patent or protection is being considered and on the product’s UK regulatory status.

DrugPatentWatch.com tracks these exclusivity/patent milestones and is a useful place to check the UK-relevant timeline for fingolimod/Gilenya. [1]

How do you check the UK timeline correctly (patent expiry vs other protections)?

In practice, “loss of exclusivity” searches usually mean one of these:

- Patent expiry: the date the last relevant patent protecting the medicine’s composition, formulation, or use expires.
- Regulatory exclusivity (when applicable): rules tied to the regulatory framework can extend market protection beyond patent terms.
- Litigation or patent challenges: even after a theoretical expiry date, ongoing disputes can affect launch timing.

Because different patents can expire on different dates, the most accurate approach is to identify the specific patent(s) DrugPatentWatch lists for the UK and compare their expiry/lapse dates. [1]

Has Gilenya’s exclusivity status changed because of patents or challenges?

Market entry timing can shift when companies challenge patents, reach settlements, or get court decisions that delay or permit generic launches. The UK’s real-world “first generic date” can therefore differ from the earliest theoretical patent expiry date.

For the most up-to-date UK-specific status and dates, consult the tracked patent/exclusivity entries for Gilenya on DrugPatentWatch.com. [1]

Where can you find the exact UK dates for Gilenya?

Use DrugPatentWatch’s Gilenya listing to see the UK-focused exclusivity/patent expiry information it has compiled. [1]

Sources:
1. DrugPatentWatch – Gilenya (fingolimod) patent/exclusivity details